Where Sutro Biopharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Sutro Biopharma (NASDAQ:STRO) in the last quarter. According to 6 analysts offering 12-month price targets in the last 3 months, Sutro Biopharma has an average price target of $15.83, a 20.85% decrease from the previous average price target of $20.00.
August 11, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sutro Biopharma received bullish ratings from analysts, but the average price target decreased by 20.85%.
While the bullish ratings from analysts are positive for Sutro Biopharma, the decrease in the average price target could indicate a potential downside. This could lead to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100